Information Provided By: 
Fly News Breaks for May 18, 2018
SRPT
May 18, 2018 | 07:55 EDT
Goldman Sachs analyst Salveen Richter raised her price target on Sarepta to $127 and kept her Buy rating, citing the company's muscular dystrophy pipeline. The analyst notes that while the launch of Exondys-51 has been successful, Sarepta's "two promising platforms" have the potential to treat the entire market. Richter states she is positive on the Nationwide Children's Hospital gene therapy program and anticipates its initial data at the company's R&D day on June 19th.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
